58869-89-9Relevant academic research and scientific papers
Decahydroquinoline amides as highly selective CB2 agonists: Role of selectivity on in vivo efficacy in a rodent model of analgesia
Manley, Peter J.,Zartman, Amy,Paone, Daniel V.,Burgey, Christopher S.,Henze, Darrell A.,Penna, Kimberly Della,Desai, Reshma,Leitl, Michael D.,Lemaire, Wei,White, Rebecca B.,Yeh, Suzie,Urban, Mark O.,Kane, Stefanie A.,Hartman, George D.,Bilodeau, Mark T.,Trotter, B. Wesley
scheme or table, p. 2359 - 2364 (2011/05/15)
A novel series of decahydroquinoline CB2 agonists is described. Optimization of the amide substituent led to improvements in CB2/CB1 selectivity as well as physical properties. Two key compounds were examined in the rat CFA model of acute inflammatory pain. A moderately selective CB2 agonist was active in this model. A CB2 agonist lacking functional CB1 activity was inactive in this model despite high in vivo exposure both peripherally and centrally.
DECAHYDROQUINOLINE ANALOGS AS CB2 RECEPTOR MODULATORS
-
Page/Page column 39, (2008/12/07)
The present invention relates to compounds represented by Formula (I): and pharmaceutically acceptable salts thereof. The present invention also provides pharmaceutical compositions comprising the instant compounds. This invention further provides methods to treat and prevent pain, respiratory and non-respiratory diseases.
